-
Innovation Ranking
NewInnovation Ranking – MKS Instruments Inc
MKS Instruments Inc (MKS) manufactures and sells subsystems, instruments, and process control solutions. The company’s product and service portfolio include capacitance manometers, mass flow controllers and meters, vacuum gauges, heater jackets, process automation controllers, foreline process traps, plasma and reactive gas sources, electroless and electrolytic plating, and surface finishing, vacuum flanges and fitting, pressure controller and valves, RF, DC and microwave generators, gas analyzers, laser-based systems for printed circuit board (PCB) manufacturing, and some others. It serves environmental monitoring, defense...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-5475
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-5475 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-0616
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-0616 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-1084
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-1084 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-8189
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-8189 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-4830
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-4830 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-8527
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-8527 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s MK-2060
Empower your strategies with our Net Present Value Model: Merck & Co Inc's MK-2060 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-1484 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-1484 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-1484 in Solid Tumor Drug Details: MK-1484 is under development for the...